Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63799 | 1.00 | PARP1 (0.43) | PARP1NR1H3NR1H2DPP4DPP7 | |
| SCHEMBL3618472 | 1.00 | PARP1 (0.43) | PARP1NR1H3NR1H2DPP4DPP7 | |
| Hydrochloric Acid SCHEMBL3618473 | 0.98 | PARP1 (0.42) | PARP1NR1H3NR1H2DPP4DPP7 | |
| Hydrochloric Acid SCHEMBL3618469 | 0.98 | PARP1 (0.42) | PARP1NR1H3NR1H2DPP4DPP7 | |
| SCHEMBL31435138 | 0.90 | PARP1 (0.42) | PARP1NR1H3NR1H2USP2SMN1; SMN2 | |
| SCHEMBL21284561 | 0.87 | PARP1 (0.41) | PARP1NR1H3NR1H2USP2SMN1; SMN2 | |
| SCHEMBL23579211 | 0.87 | PARP1 (0.42) | PARP1NR1H3NR1H2USP2SMN1; SMN2 | |
| SCHEMBL12845197 | 0.87 | PARP1 (0.42) | PARP1NR1H3NR1H2USP2SMN1; SMN2 | |
| SCHEMBL30050599 | 0.87 | PARP1 (0.42) | PARP1NR1H3NR1H2USP2SMN1; SMN2 | |
| SCHEMBL30801268 | 0.86 | PARP1 (0.40) | PARP1NR1H3NR1H2USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| CN-115745960-B | Compound containing quinolinone amide, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-08-30 | — | — | CN | disclosed |
| CN-117794525-A | Anticancer compounds | 加利福尼亚大学董事会 | 2024-03-29 | — | — | CN | disclosed |
| US-20230234942-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-11633415-B2 | Compounds and methods useful for treating or preventing cancers | THE BROAD INSTITUTE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| CN-115745960-A | Quinolinone amide-containing compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-03-07 | — | — | CN | disclosed |
| US-20220096513-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING CANCERS | THE BROAD INSTITUTE, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| US-10590139-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA INC. (US) | 2020-03-17 | — | — | US | disclosed |
| CN-101638423-A | Phloridzin derivative as well as preparation method and application thereof | 3D IND TECHNOLOGY RES I CO LTD | 2010-02-03 | — | — | CN | disclosed |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
| EP-1989188-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | AMR TECHNOLOGY, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1871765-A2 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007100852-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203124-A1 | Therapeutic Piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
| WO-2006081230-A2 | 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203124-A1 | Therapeutic Piperazines | PDE4A, PDE4B, PDE12 | PARP1 1492/4885NR1H3 1001/4885NR1H2 744/4885 |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | PARP1 3608/4885NR1H3 21/4885NR1H2 14/4885 |
| US-20220096513-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING CANCERS | CSNK1A1, CSNK2A1, CSNK2A3 | PARP1 179/4885NR1H3 1625/4885NR1H2 1681/4885 |
| US-20230234942-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, CLN6 | PARP1 3545/4885NR1H3 545/4885NR1H2 426/4885 |
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | PARP1 1738/4885NR1H3 4594/4885NR1H2 4529/4885 |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PARP1 1145/4885NR1H3 2510/4885NR1H2 2108/4885 |
| US-10590139-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | COL2A1, COL1A1, IFNAR1 | PARP1 3377/4885NR1H3 3279/4885NR1H2 2590/4885 |
| US-11633415-B2 | Compounds and methods useful for treating or preventing cancers | CSNK1A1, CSNK2A1, CSNK2A3 | PARP1 179/4885NR1H3 1625/4885NR1H2 1681/4885 |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | IDH1, IDH3B, IDH3A | PARP1 1121/4885NR1H3 1964/4885NR1H2 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.